The clinical and pathological characteristics of lipid-rich carcinoma of the breast: an analysis of 98 published patients

Springer Science and Business Media LLC - Tập 23 Số 1
Mengdi Zhang1, Dongqing Pu1, Guangxi Shi2, Jingwei Li2
1Shandong University of Traditional Chinese Medicine, No. 16369 Jingshi Road, Lixia District, Jinan City, 250014, Shandong Province, China
2Department of Thyroid and Breast Diagnosis and Treatment Center, Affiliated Hospital of Shandong, University of Traditional Chinese Medicine, No. 16369 Jingshi Road, Lixia District, Jinan City, 250014, Shandong Province, China

Tóm tắt

Abstract Background Due to the small number of cases and few literature reports, the clinical treatment and prognosis of lipid-rich carcinoma of the breast are not summarized, which will lead to misdiagnosis and mistreatment and delay the patient’s condition. This study collected published case reports and analyzed the clinical characteristics of lipid-rich carcinoma of the breast in order to provide reference for early diagnosis and treatment of the disease. Methods We performed a search using the PubMed, ClinicalTrials.gov, Embase, Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases for publicly published case reports of lipid-rich carcinoma of the breast and obtained basic information of the patients such as country, age, sex, onset site, surgical method, pathology, postoperative treatment, follow-up time, and outcome (Table 9). The data were analyzed using Statistical Product Service Solutions (SPSS). Results The mean age of the patients at diagnosis was 52.79 years and the median age was 53 years. Breast masses were the main clinical manifestations, with the upper outer quadrant (53.42%) being the most common. The treatment for lipid-rich carcinoma of the breast is mainly surgery plus postoperative adjuvant radiotherapy and chemotherapy. According to the results of this study, the surgical method recommended modified radical mastectomy (46.59%). Lymph node metastasis was found in 50.60% of the patients at the time of the first diagnosis. Patients who received postoperative adjuvant chemotherapy and radiotherapy had the highest disease-free survival and overall survival. Conclusion Lipid-rich carcinoma of the breast has a short course of disease and early lymphatic or blood metastasis, and its prognosis is poor. In this study, we summarize the clinical and pathological characteristics to provide ideas for the early diagnosis and treatment of lipid-rich carcinoma of the breast.

Từ khóa


Tài liệu tham khảo

Aboumrad MH, Horn RC Jr, Fine G. Lipid-secreting Mammary Carcinoma. Report of a Case Associated with Paget’s Disease of the Nipple. Cancer. 1963;16:521–5. https://doi.org/10.1002/1097-0142(196304)16:4<521::aid-cncr2820160414>3.0.co;2-b. Epub 1963/04/01.

Ramos CV, Taylor HB. Lipid-Rich Carcinoma of the breast. A clinicopathologic analysis of 13 examples. Cancer. 1974;33(3):812–9. https://doi.org/10.1002/1097-0142(197403)33:3<812::aid-cncr2820330328>3.0.co;2-4. Epub 1974/03/01.

Cong Y, Lin J, Qiao G, Zou H, Wang X, Li X, et al. Lipid-Rich Carcinoma of the breast: a report of two cases and a literature review. Oncol Lett. 2015;9(4):1729–32. https://doi.org/10.3892/ol.2015.2924. Epub 2015/03/20.

Wrba F, Ellinger A, Reiner G, Spona J, Holzner JH. Ultrastructural and immunohistochemical characteristics of lipid-rich carcinoma of the breast. Virchows Archiv A Pathological anatomy and histopathology. 1988;413(5):381–5. https://doi.org/10.1007/bf00716986. Epub 1988/01/01.

Kurisu Y, Tsuji M, Shibayama Y, Takahashi Y, Nohara T. Intraductal lipid-rich carcinoma of the breast with a component of glycogen-rich carcinoma. J breast cancer. 2012;15(1):135–8. https://doi.org/10.4048/jbc.2012.15.1.135. Epub 2012/04/12.

Umekita Y, Yoshida A, Sagara Y, Yoshida H. Lipid-secreting carcinoma of the breast: a Case Report and Review of the literature. Breast cancer (Tokyo Japan). 1998;5(2):171–3. https://doi.org/10.1007/bf02966690. Epub 2000/11/25.

Böcker W. [Who classification of breast tumors and tumors of the female genital Organs: Pathology and Genetics]. Verh Dtsch Ges Pathol. 2002;86:116–9. Epub 2003/03/22.

van Bogaert LJ, Maldague P. Histologic variants of lipid-secreting carcinoma of the breast. Virchows Archiv A Pathological anatomy and histology. 1977;375(4):345–53. https://doi.org/10.1007/bf00427064. Epub 1977/10/07.

Aida Y, Takeuchi E, Shinagawa T, Tadokoro M, Inoue S, Omata Y, et al. Fine needle aspiration cytology of lipid-secreting carcinoma of the breast. A Case Report. Acta Cytol. 1993;37(4):547–51. Epub 1993/07/01.

Shi P, Wang M, Zhang Q, Sun J. Lipid-Rich Carcinoma of the breast. A clinicopathological study of 49 cases. Tumori. 2008;94(3):342–6. Epub 2008/08/19.

Wu Yigang MA, Yuan S, et al. Diagnosis and treatment of five cases of secretory lipid carcinoma of breast [J]. World J Integr Traditional Chin Western Med. 2009;4(06):437–8.

Liu Ling TY, Shi, Jiafeng. A case of lipid-rich breast Cancer with Intraciliary metastasis [J]. Chin J Ophthalmol. (2001) (02):74.

Ding Longlong WK. Research Progress of Top2a Gene in Predicting the Efficacy of Anthracyclines in the treatment of breast Cancer [J]. Chin J Practical Surg. 2014;34(05):456–8.

Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, et al. Erbb2 and Top2a in breast Cancer: a comprehensive analysis of gene amplification, rna levels, and protein expression and their influence on prognosis and prediction. Clin cancer research: official J Am Association Cancer Res. 2010;16(8):2391–401. https://doi.org/10.1158/1078-0432.Ccr-09-2471. Epub 2010/04/08.

Schildhaus HU, Schroeder L, Merkelbach-Bruse S, Binot E, Büttner R, Kuhn W, et al. Therapeutic strategies in male breast Cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes. Breast (Edinburgh Scotland). 2013;22(6):1066–71. https://doi.org/10.1016/j.breast.2013.08.008. Epub 2013/10/02.

Shuai P. [Expressions of Her2 and Topo Iiα in Breast Cancer and Its Clinical Significance]. Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences (2016) 41(11):1143-7. Epub 2016/12/10. https://doi.org/10.11817/j.issn.1672-7347.2016.11.005

Hainaut P, Hollstein M. P53 and Human Cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81–137. https://doi.org/10.1016/s0065-230x(08)60785-x. Epub 1999/11/05.

Zhang Dejiang CK, Wang Y. Expression and significance of Fas and Fasl in normal breast and breast Cancer [J]. J Tumor Prev Treat. 2000;06585–7. https://doi.org/10.16073/j.cnki.cjcpt.2000.06.013

ZHOU, Guang-zheng CS, He GU. Zhang Lili. Expression and clinical significance of Topoiiα, Ki-67 and P53 in Triple negative breast Cancer [J]. Progress of Modern General surgery in China. (2017) 20(12):944–7.

Yang Siyuan TL, Zhang Y, Qingsong L. Expression and correlation analysis of Topo II and P53 in breast Cancer [J]. World Latest Medical Information Abstract. 2019;19(71):248–50. https://doi.org/10.19613/j.cnki.1671-3141.2019.71.136

An X, Xu F, Luo R, Zheng Q, Lu J, Yang Y, et al. The Prognostic significance of Topoisomerase Ii alpha protein in early stage luminal breast Cancer. BMC Cancer. 2018;18(1):331. https://doi.org/10.1186/s12885-018-4170-7. Epub 2018/03/29.

Li Zhihua LQ, Jianping X. Meta-analysis of correlation between P53 expression in breast Cancer tissue and efficacy of Neoadjuvant chemotherapy [J]. Chin J Cancer Prev Treat. 2015;22(03):221–6. https://doi.org/10.16073/j.cnki.cjcpt.2015.03.016

Guan B, Wang H, Cao S, Rao Q, Wang Y, Zhu Y, et al. Lipid-Rich Carcinoma of the breast clinicopathologic analysis of 17 cases. Annals of diagnostic pathology. 2011;15(4):225–32. https://doi.org/10.1016/j.anndiagpath.2010.10.006. Epub 2011/03/15.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 23 Số 1

Thông tin tác giả